Safety Profile, Toxicokinetic, and Intestinal Absorption Differences of a Naturally-Derived Anti-Rheumatic Drug, Sinomenine Hydrochloride, in Normal and Arthritic Rats
<b>Background/Objective</b>: Sinomenine hydrochloride (SH), a natural anti-rheumatic drug derived from the Chinese medicinal plant <i>Sinomenium acutum</i>, demonstrates disease-modifying properties but lacks comprehensive safety and toxicokinetic (TK) comparisons between physiological and pathological states. This study evaluated SH's safety profile, TK parameters, and intestinal absorption differences in adjuvant-induced arthritis (AIA) and normal rats. <b>Methods</b>: Safety assessments determined median lethal doses (LD<sub>50</sub>) in female Sprague Dawley rats. TK parameters were analyzed via a validated ultrahigh performance liquid chromatography-tandem mass spectrometry approach after single oral administration of 600 mg/kg SH. Plasma protein binding (PPB) were measured using equilibrium dialysis. Intestinal absorption was evaluated through everted gut sac experiments, with P-glycoprotein (P-gp) inhibition tested via verapamil co-administration. <b>Results</b>: LD<sub>50</sub> values revealed AIA rats tolerated SH better than normal rats (1179 vs. 805 mg/kg). TK analysis showed that C<sub>max</sub>, AUC<sub>(0-t)</sub>, and AUC<sub>(0-∞)</sub> of SIN in normal rats were 2.01, 1.94, and 2.14 times higher than in AIA rats, respectively, while CL/F and V/F in AIA rats were 2.24 times greater. In addition, the PPB of SIN in normal rats was 2 times greater than that in AIA rats. AIA rats exhibited significantly lower SH absorption in the jejunum and ileum compared to normal rats. Notably, verapamil co-administration markedly increased SH absorption across most intestinal segments. <b>Conclusions</b>: Pathological states significantly alter SH's safety and TK profiles. Enhanced tolerance in AIA rats correlates with reduced intestinal absorption via altered P-gp activity and decreased PPB. These findings emphasize the necessity of disease-specific evaluations for optimizing SH's therapeutic safety in pathological contexts.
Authors
- Jianye Yan (ORCID: https://orcid.org/0000-0002-6811-5440)
- Hong Huang
- Feichi Wu
- Junjie He (ORCID: https://orcid.org/0000-0001-6447-7893)
- Gejing Li
- Lin Ye (ORCID: https://orcid.org/0000-0002-3304-4558)
- Ye Zhang (ORCID: https://orcid.org/0009-0000-4883-8097)
- Liang Liu (ORCID: https://orcid.org/0009-0001-8707-7486)
- Yini He
- Xiong Cai
Institutions
- Guangzhou University of Chinese Medicine (CN)
- Hunan University of Traditional Chinese Medicine (CN)
- Hua Medicine (China) (CN)
Publication Details
- Journal
- Pharmaceutics
- Published
- 2025-04-07
- DOI
- https://doi.org/10.3390/pharmaceutics17040484
- Primary Topic
- Berberine and alkaloids research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- China Postdoctoral Science Foundation